German Cancer Research Center (DKFZ)
Hopp Children´s Cancer Center Heidelberg
Name of PI: Stefan Pfister
Email: s.pfister(at)kitz-heidelberg.de
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg
Germany
www.dkfz.de
www.kitz-heidelberg.de
Team members working on ITCC-P4 with their position and email address
- Anna-Lisa Böttcher, Scientific Project Management, a.boettcher(at)kitz-heidleberg.de
- Marcel Kool, Groupleader, m.kool(at)kitz-heidelberg.de
- Olaf Witt, PI, o.witt(at)kitz-heidelberg.de
- Natalie Jäger, Groupleader, n.jaeger(at)kitz-heidelberg.de
- David Jones, PI, david.jones(at)kitz-heidelberg.de
- Frank Westermann, PI, f.Westermann(at)kitz-heidelberg.de
- Aniello Federico, PostDoc, a.federico(at)kitz-heidelberg.de
- Norman Mack, Technician, n.mack(at)kitz-heidleberg.de
- Benjamin Schwalm, Technician, b-Schwalm(at)kitz-heidelberg.de
Company presentation
The German Cancer Research Center (DKFZ) has a worldwide reputation of excellence in basic and translational cancer research, and is one of the leading research centers in the field. Established more than 50 years ago as a foundation under public law, the DKFZ is funded by the Federal German Government, the State of Baden-Württemberg and third-party funding. The DKFZ is a member of the Helmholtz Association – Germany’s largest research organization. The strategic goals of the DKFZ are to contribute towards a better understanding of fundamental processes in cancer and to develop innovative methods of cancer diagnostics and therapy.
The newly founded Hopp Children´s Cancer Center Heidelberg (KiTZ), a joint venture between the DKFZ, Heidelberg University Hospital and Heidelberg University, combines outstanding pre-clinical, translational and state-of-the-art clinical expertise in pediatric oncology to provide world-leading science and clinical care under one roof.
Amongst others, our research focuses on the genetic and epigenetic characterization of the major tumor entities occurring in childhood, the development of faithful models through a better understanding of their cellular origin, and the preclinical testing of new treatment options using these models.
Furthermore, we are running the KiTZ Clinical Trial Unit - one of the most active and visible pediatric clinical trials units in Europe with a special focus on molecular stratification and neurooncology.